Combinations of ␤-lactams with clavulanate are currently being investigated for tuberculosis treatment. Since Mycobacterium tuberculosis produces a broad spectrum ␤-lactamase, BlaC, the success of this approach could be compromised by the emergence of clavulanate-resistant variants, as observed for inhibitor-resistant TEM variants in enterobacteria. Previous analyses based on site-directed mutagenesis of BlaC have led to the conclusion that this risk was limited. Here, we used a different approach based on determination of the crystal structure of ␤-lactamase Bla MAb 
P
roduction of the broad-spectrum Ambler class A ␤-lactamase BlaC (1, 2) is a major contributor to intrinsic resistance of Mycobacterium tuberculosis to most ␤-lactams (3). Combining these drugs with a BlaC inhibitor has been recognized for decades as a potential approach for the treatment of tuberculosis (4, 5) . However, such combinations have never been broadly used or evaluated in controlled trials, despite limited evidence of their efficacy in animal models and in patients (6) . The demonstration that BlaC is slowly (1) but irreversibly (7) inactivated by clavulanate has renewed the interest for this approach. This ␤-lactamase inefficiently hydrolyzes ␤-lactams of the carbapenem class, such as meropenem (7) and the orally bioavailable ␤-lactam faropenem (8) (k cat /K m , 3.0 ϫ 10 2 M Ϫ1 s Ϫ1 and 6.5 ϫ 10 2 M Ϫ1 s Ϫ1 , respectively). In the presence of clavulanate (2.5 g/ml), meropenem is uniformly active against extensively drug-resistant (XDR) isolates of M. tuberculosis (MICs, Յ1.25 g/ml) (7). Faropenem efficiently kills M. tuberculosis even in the absence of clavulanate (8) . In addition, faropenem was superior to isoniazid and meropenem in its ability to induce rapid cytolysis and to eliminate a subpopulation of nongrowing but metabolically active bacilli (8) . These observations raised the possibility of using ␤-lactamclavulanate combinations for the treatment of XDR tuberculosis (6, 7, 9) , and clavulanate combined with meropenem or faropenem is currently being evaluated in an early trial of bactericidal activity (https://clinicaltrials.gov/ct2/show/NCT02349841).
We have recently identified and characterized a class A ␤-lactamase in Mycobacterium abscessus (Bla MAb ) which is closely related to BlaC (48% sequence identity) (11) . In contrast to BlaC, which is irreversibly inactivated by clavulanate, Bla MAb hydrolyzes this drug with a relatively high catalytic efficiency (k cat /K m , 2.1 ϫ 10 5 M Ϫ1 s Ϫ1 ) (11, 12) . In this report, we have determined the crystal structure of Bla MAb in order to perform structure-assisted site-directed mutagenesis of BlaC and identify residues essential for acylenzyme stability. We show that a single amino acid substitution, which restores the canonic SDN motif (SDG¡SDN) in BlaC, is sufficient to abolish inhibition of BlaC by clavulanate due to efficient hydrolysis of this inhibitor (k cat /K m , Ͼ2.1 ϫ 10 4 M Ϫ1 s Ϫ1 ). These results suggest that resistance to ␤-lactam-clavulanate combinations may emerge under treatment.
MATERIALS AND METHODS
␤-Lactamase production and purification. We have previously reported the construction of derivatives of plasmid pET-tobacco etch virus (TEV) encoding residues 31 to 289 of Bla MAb and residues 39 to 306 of BlaC fused to a vector-encoded N-terminal 6ϫHis tag followed by a TEV cleavage site (MHHHHHHENLYFQGHM) (11) . For the BlaC G 132 N variant, a synthetic gene (Genecust) was cloned into the same vector. Bacteria were grown in brain-heart infusion (BHI) broth supplemented with kanamycin (50 g/ml) at 37°C under vigorous shaking until the optical density at 600 nm (OD 600 ) reached 0.8. Isopropyl ␤-D-1-thiogalactopyranoside (0.5 mM) was added, and incubation continued at 16°C for 18 h. Bacteria were harvested by centrifugation, resuspended in 25 mM Tris-HCl (pH of 7.5) containing 300 mM NaCl (buffer A), and lysed by sonication. The enzymes were purified from clarified lysates by affinity chromatography (Ni-NTA agarose; Sigma-Aldrich) and size-exclusion chromatography in buffer A (Superdex 200 HL26/60; Amersham Pharmacia Biotech). For crystallogenesis, purified Bla MAb was cleaved with 6ϫHis-labeled TEV protease. The polyhistidine tag and the TEV protease were removed by nickel-affinity chromatography. The ␤-lactamase was purified by a second size-exclusion chromatography in buffer A and concentrated to 10 mg/ml (Amicon Ultra15 10K; Merck Millipore, Ltd.).
Crystallization and data collection. The hanging-drop diffusion method was used for crystallization of Bla MAb . The composition of the well consisted of 0.1 M sodium acetate, 0.1 2-(N-morpholino)ethanesulphonic acid (MES; pH of 6.4), and 32% polyethylene glycol monomethyl ether 2000, which made the final pH of the solution 5.0. Protein at a concentration of 10 mg/ml was mixed with the well solution in a 1:1 ratio and incubated at 293 K. Glycerol (20%) was added to the crystallization solution as a cryoprotector, and X-ray diffraction data were collected at 100 K on beamline Proxima 1 at the Soleil synchrotron using a Pilatus detector. The images were integrated with the XDS program (13) and processed using the CCP4 program suite (14) . The structure of M. tuberculosis BlaC (Protein Data Bank [PDB] entry 2GDN) was used to phase the data with the Phaser program, as implemented in the CCP4 program suite (15) . The initial models were completed and adjusted with the program Coot (16) . Refinement was performed using Refmac (17) . Statistics for data collection appear in Table 1 .
Determination of kinetic parameters. The kinetic parameters k cat and K m for hydrolysis of ␤-lactams were determined by spectrophotometry at 20°C in 100 mM MES buffer (pH of 6.4), as previously described (11) . Kinetic data were acquired with a spectrophotometer (Cary 100-Bio; Varian) at 486 nm for nitrocefin (⌬ε ϭ 14,600 M Ϫ1 cm Ϫ1 ), 227 nm for clavulanate (⌬ε ϭ Ϫ2,500 M Ϫ1 cm Ϫ1 ), 244 nm for amoxicillin (⌬ε ϭ Ϫ1,600 M Ϫ1 cm Ϫ1 ), 298 nm for meropenem (⌬ε ϭ Ϫ7,300 M Ϫ1 cm Ϫ1 ), and 258 nm for faropenem (⌬ε ϭ Ϫ2,200 M Ϫ1 cm Ϫ1 ). The k cat and K m parameters were obtained using iterative linear least-squares fit of the data to the Henri-Michaelis equation,
To assay for ␤-lactamase inhibition, the enzyme was incubated with clavulanate (200 M) for various times, and kinetic data were acquired with a stopped-flow apparatus (RX-2000; Applied Biophysics) coupled to a spectrophotometer (Cary 300; Varian), as previously described (11) .
Mass spectrometry analyses. The formation of drug-enzyme adducts was tested by incubating the enzymes (10 M) with clavulanate (1,000 M) at 20°C in water (11) . The reaction mixture was injected into a mass spectrometer (Qstar Pulsar I; Applied Biosystems) at a flow rate of 0.05 ml/min (50% acetonitrile, 49.5% water, and 0.5% formic acid; per volume). Spectra were acquired in the positive mode, as previously described (11) .
Protein structure accession number. The structure described in this paper has been deposited in PDB under code 4YFM.
RESULTS AND DISCUSSION
Determination of the structure of Bla MAb and comparison with BlaC. The crystal structure of M. abscessus Bla MAb was solved using molecular replacement and refined to 1.4 Å resolution. The final R factor and R free values for all reflections were 0.14 and 0.17, respectively ( Table 1 ). The refined structure includes 259 of the 261 residues of the TEV cleavage product of recombinant Bla MAb . The overall structures of M. abscessus Bla MAb and M. tuberculosis BlaC are very similar, with a root mean square difference (RMSD) of 1.2 Å for 251 aligned C-␣ atoms (44% sequence identity). In addition, the conformation of the side chain of the catalytic residues, S 70 , K 73 , and E 166 according to the Ambler numbering (18), is highly conserved in the two structures. However, comparison of residues within the enzyme catalytic cavities revealed differences in Ambler positions 105, 132, and 237 that were occupied by W, N, and G, respectively, in Bla MAb and by I, G, and T, respectively, in BlaC (Fig. 1) . In addition, Ambler position 276 was occupied by K and by E in Bla MAb and BlaC, respectively. These four positions represented the most significant differences in the catalytic pocket between the two orthologs.
Hydrolysis of clavulanate by derivatives of BlaC. ( Table 2 ). The G 132 N substitution alone, and the combination of I 105 W with G 132 N, had similarly profound impacts on the interaction of the ␤-lactamase with clavulanate. The G 132 N substitution was sufficient to switch the interaction of BlaC with clavulanate from irreversible inactivation (7, 9) to efficient hydrolysis. The substitution did not impair the activity of BlaC for hydrolysis of representatives of the various classes of ␤-lactams, including meropenem (carbapenem), faropenem (penem), nitrocefin (cephalosporin), and amoxicillin (penam) ( Table 3 ). This is in marked contrast with previous analyses of BlaC aimed at exploring the potential acquisition of clavulanate resistance (19, 20) . These analyses only identified amino acid substitutions that increased K i , often in association with impaired ␤-lactamase activity, in the absence of clavulanate hydrolysis (19, 20) . Of note, a half-life of 12 h has been reported for the adduct resulting from acylation of wild-type BlaC by clavulanate, implying a k cat value for clavulanate hydrolysis in the order of 10 Ϫ5 s Ϫ1 (21) . Thus, the G 132 N substitution resulted in a more than 10 4 -fold increase in the value of k cat (Table 3) .
It has been previously reported that time-dependent inactivation of class A ␤-lactamases by clavulanate can be extremely slow and only detectable at very high drug-to-enzyme ratios (22) . This possibility was investigated by following the hydrolysis of nitrocefin (100 M) by the BlaC G 132 N variant (5 nM) in the presence of clavulanate (150 and 500 M), resulting in clavulanate-to-enzyme molar ratios of 30,000:1 and 100,000:1, respectively. Timedependent inactivation of the BlaC G 132 N variant was not observed under these conditions (Fig. 2) . The SDN motif is present in class A ␤-lactamases that are efficiently inhibited by clavulanate, such as TEM-1. Inhibitor-resistant TEM ␤-lactamases rarely harbor amino acid substitutions within the motif SDN, and the substitution affects the first residue of the motif (GDN instead of SDN) (23) . In contrast, the polymorphism in Bla MAb and BlaC affects the third residue (SDN instead of SDG). In mycobacteria, inhibition of SDN-containing class A ␤-lactamases has been reported for Mycobacterium smegmatis (3) and Mycobacterium fortuitum (24, 25) . Thus, the impact of the G 132 N substitution on clavulanate hydrolysis appears to be specific to BlaC.
Pathway of clavulanate hydrolysis by BlaC G 132 N. A mechanism of inhibition of BlaC by clavulanate has been proposed based on mass spectrometry (7) and crystallography of the acylenzyme (26) . According to this model (Fig. 3A) , acylation of the active-site Ser residue and rupture of the ␤-lactam bond is followed by rupture of the remaining ring and formation of an acyclic imine. The resulting adduct undergoes rapid decarboxylation to generate a stable acylenzyme following isomerization of the imine to form an ␣,␤-trans-enamine. Mass spectrometry analysis showed that interaction of the BlaC G 132 N variant with clavulanate may lead to the same sequence of events (Fig. 3B) , since acylation of BlaC and the BlaC G 132 N variant by clavulanate led to the sequential formation of two covalent adducts displaying the same mass increments. However, clavulanate decarboxylation within the BlaC G 132 N active site was followed by hydrolysis of the acylenzyme, leading to enzyme turnover. This may result either from impaired tautomerization or increased hydrolysis of the tautomers or from both.
Traceability of the SDN/SDG polymorphism in mycobacteria. Phylogenic trees showing inferred relationships between the sequences of mycobacterial class A ␤-lactamases (Fig. 4) and of housekeeping genes (27, 28) revealed similar topologies. This observation and the ubiquitous presence of the same ␤-lactamase gene in all members of the same species indicate, as expected, that class A ␤-lactamases are stably inherited following vertical gene transfer. Figure 4 also suggests that the SDN/SDG polymorphism defines two homogenous lines of descent comprising rapidly growing mycobacteria, including M. abscessus (SDN), and slowly growing mycobacteria, including M. tuberculosis (SDG). As discussed above, the presence of SDN in the M. abscessus phylum is not predictive of the inhibitor-versus-substrate status of clavulanate, since this drug is a substrate of Bla MAb (11) and an inhibitor of BlaS from M. smegmatis (3) .
Conclusion. Chemotherapy of tuberculosis is unusually long in comparison to most bacterial infectious diseases. The standard treatment lasts for 6 months, and much longer therapy is required in case of resistance to the most active antibiotics (29) . Prolonged exposure to the selective pressure of the drugs is associated with a risk of resistance due to acquisition of mutations, in particular in the case of poor compliance. Thus, assessment of the risk of the emergence of resistance is relevant to the evaluation of the efficacy of new treatments. Our data show that the ␤-lactam-clavulanate combinations are at risk for the development of resistance, since a single substitution in BlaC was sufficient to fully abolish inhibition by clavulanate without impairing hydrolysis of other ␤-lactams (Table 3) . However, this observation does not necessarily imply that the G 132 N substitution is sufficient for resistance, since important differences have been previously observed between the evaluation of in vitro inhibition of BlaC variants and the expression of resistance. Such differences have been attributed to a combination of time-dependent inhibition of BlaC, which has not been observed for our G 132 N variant (Fig. 2) , and of the duration (24 h) of the M. tuberculosis doubling time (20) . It is worth noting that faropenem has been reported to be similarly active in vitro in the presence or absence of clavulanate, presumably because this drug inactivates the L,D-transpeptidase targets more rapidly than meropenem (8) . The ongoing clinical trial comparing the efficacy of clavulanate associated with meropenem and faropenem will provide a first evaluation of the clinical relevance of these observations.
